Literature DB >> 23103626

Galectin-3 gene silencing inhibits migration and invasion of human tongue cancer cells in vitro via downregulating β-catenin.

Dong Zhang1, Zheng-gang Chen, Shao-hua Liu, Zuo-qing Dong, Martin Dalin, Shi-san Bao, Ying-wei Hu, Feng-cai Wei.   

Abstract

AIM: Galectin-3 (Gal-3) is a member of the carbohydrate-binding protein family that contributes to neoplastic transformation, tumor survival, angiogenesis, and metastasis. The aim of this study is to investigate the role of Gal-3 in human tongue cancer progression.
METHODS: Human tongue cancer cell lines (SCC-4 and CAL27) were transfected with a small-interfering RNA against Gal-3 (Gal-3-siRNA). The migration and invasion of the cells were examined using a scratch assay and BD BioCoat Matrigel Invasion Chamber, respectively. The mRNA and protein levels of β-catenin, Akt/pAkt, GSK-3β/pGSK-3β, MMP-9 in the cells were measured using RT-PCR and Western blotting, respectively.
RESULTS: Transient silencing of Gal-3 gene for 48 h significantly suppressed the migration and invasion of both SCC-4 and CAL27 cells. Silencing of Gal-3 gene significantly decreased the protein level of β-catenin, leaving the mRNA level of β-catenin unaffected. Furthermore, silencing Gal-3 gene significantly decreased the levels of phosphorylated Akt and GSK-3β, and suppressed the mRNA and protein levels of MMP-9 in the cells.
CONCLUSION: Our data suggest that Gal-3 mediates the migration and invasion of tongue cancer cells in vitro via regulating the Wnt/β-catenin signaling pathway and Akt phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23103626      PMCID: PMC4086502          DOI: 10.1038/aps.2012.150

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   7.169


  41 in total

1.  Activation of the Wnt/beta-catenin signaling pathway during oral carcinogenesis process is not influenced by the absence of galectin-3 in mice.

Authors:  Juliana Moreira de Almeida Sant'ana; Roger Chammas; Fu-Tong Liu; Suely Nonogaki; Sérgio Vitorino Cardoso; Adriano Mota Loyola; Paulo Rogério de Faria
Journal:  Anticancer Res       Date:  2011-09       Impact factor: 2.480

2.  β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.

Authors:  Stephan P Tenbaum; Paloma Ordóñez-Morán; Isabel Puig; Irene Chicote; Oriol Arqués; Stefania Landolfi; Yolanda Fernández; José Raúl Herance; Juan D Gispert; Leire Mendizabal; Susana Aguilar; Santiago Ramón y Cajal; Simó Schwartz; Ana Vivancos; Eloy Espín; Santiago Rojas; José Baselga; Josep Tabernero; Alberto Muñoz; Héctor G Palmer
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

3.  Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis.

Authors:  Ulrike Stein; Franziska Arlt; Janice Smith; Ulrike Sack; Pia Herrmann; Wolfgang Walther; Margit Lemm; Iduna Fichtner; Robert H Shoemaker; Peter M Schlag
Journal:  Neoplasia       Date:  2011-02       Impact factor: 5.715

4.  Multifaceted role of galectin-3 on human glioblastoma cell motility.

Authors:  Charles Debray; Pierre Vereecken; Nathalie Belot; Peggy Teillard; Jean-Pierre Brion; Massimo Pandolfo; Roland Pochet
Journal:  Biochem Biophys Res Commun       Date:  2004-12-24       Impact factor: 3.575

Review 5.  Galectin-3 in apoptosis, a novel therapeutic target.

Authors:  Pratima Nangia-Makker; Susumu Nakahara; Victor Hogan; Avraham Raz
Journal:  J Bioenerg Biomembr       Date:  2007-02       Impact factor: 2.945

6.  Regulation of prostate cancer progression by galectin-3.

Authors:  Yi Wang; Pratima Nangia-Makker; Larry Tait; Vitaly Balan; Victor Hogan; Kenneth J Pienta; Avraham Raz
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

7.  Gypenosides inhibited invasion and migration of human tongue cancer SCC4 cells through down-regulation of NFkappaB and matrix metalloproteinase-9.

Authors:  Kung-Wen Lu; Ming-Li Tsai; Jung-Chou Chen; Shu-Chun Hsu; Te-Chun Hsia; Meng-Wei Lin; An-Cheng Huang; Yung-Hsien Chang; Siu-Wan Ip; Hsu-Feng Lu; Jing-Gung Chung
Journal:  Anticancer Res       Date:  2008 Mar-Apr       Impact factor: 2.480

8.  Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells.

Authors:  Nachman Mazurek; Yun Jie Sun; Kai-Feng Liu; Michael Z Gilcrease; Wendy Schober; Pratima Nangia-Makker; Avraham Raz; Robert S Bresalier
Journal:  J Biol Chem       Date:  2007-04-09       Impact factor: 5.157

9.  Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity.

Authors:  Shumei Song; Nachman Mazurek; Chunming Liu; Yunjie Sun; Qing Qing Ding; Kaifeng Liu; Mien-Chie Hung; Robert S Bresalier
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

10.  Interactions between β-catenin and the HSlo potassium channel regulates HSlo surface expression.

Authors:  Shumin Bian; Jun-Ping Bai; Hannah Chapin; Cathy Le Moellic; Huiping Dong; Michael Caplan; Fred J Sigworth; Dhasakumar S Navaratnam
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

View more
  27 in total

Review 1.  Galectin-3 and cancer stemness.

Authors:  Pratima Nangia-Makker; Victor Hogan; Avraham Raz
Journal:  Glycobiology       Date:  2018-04-01       Impact factor: 4.313

Review 2.  Targeting mitotic pathways for endocrine-related cancer therapeutics.

Authors:  Shivangi Agarwal; Dileep Varma
Journal:  Endocr Relat Cancer       Date:  2017-06-14       Impact factor: 5.678

3.  Galectin-3 expressed on different lung compartments promotes organ specific metastasis by facilitating arrest, extravasation and organ colonization via high affinity ligands on melanoma cells.

Authors:  Manohar C Dange; Nithya Srinivasan; Shyam K More; Sanjay M Bane; Archana Upadhya; Arvind D Ingle; Rajiv P Gude; Rabindranath Mukhopadhyaya; Rajiv D Kalraiya
Journal:  Clin Exp Metastasis       Date:  2014-06-21       Impact factor: 5.150

4.  Diagnostic and Prognostic Significance of Serum and Tissue Galectin 3 Expression in Patients with Carcinoma of the Bladder.

Authors:  Hoda El Gendy; Bothina Madkour; Sara Abdelaty; Fayza Essawy; Dina Khattab; Olfat Hammam; Hani H Nour
Journal:  Curr Urol       Date:  2014-08-20

5.  Overexpression of galectin2 (LGALS2) predicts a better prognosis in human breast cancer.

Authors:  Mandika Chetry; Adheesh Bhandari; Ruiling Feng; Xinming Song; Pintian Wang; Jing Lin
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 4.060

6.  Muc-1 promotes migration and invasion of oral squamous cell carcinoma cells via PI3K-Akt signaling.

Authors:  Ping Li; Li Ying Xiao; Hong Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Expression of APC protein during tongue malignant transformation in galectin-3-deficient mice challenged by the carcinogen 4-nitroquniline-n-oxide.

Authors:  Marcus Vinicius Rodrigues de Souza; João Paulo Silva Servato; Adriano Mota Loyola; Sérgio Vitorino Cardoso; Roger Chammas; Fu-Tong Liu; Marcelo José Barbosa Silva; Paulo Rogério de Faria
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

8.  Overexpression of miRNA-9 enhances galectin-3 levels in oral cavity cancers.

Authors:  Yunxia Wan; Xi Zhang; Kai Dun Tang; Tony Blick; Liz Kenny; Erik W Thompson; Chamindie Punyadeera
Journal:  Mol Biol Rep       Date:  2021-05-21       Impact factor: 2.316

9.  Galectin-4 serves as a prognostic biomarker for the early recurrence / metastasis of hepatocellular carcinoma.

Authors:  Zhixiong Cai; Yongyi Zeng; Bo Xu; Yunzhen Gao; Sen Wang; Jinhua Zeng; Lihong Chen; Aimin Huang; Xiaolong Liu; Jingfeng Liu
Journal:  Cancer Sci       Date:  2014-10-27       Impact factor: 6.716

10.  Eosinophil-expressed galectin-3 regulates cell trafficking and migration.

Authors:  Xiao Na Ge; Sung Gil Ha; Fu-Tong Liu; Savita P Rao; P Sriramarao
Journal:  Front Pharmacol       Date:  2013-04-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.